APL-话题@MedSci

#APL#

42篇内容 | 2205人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1509522, encodeId=c4fa150952238, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=NEJM：Caplacizumab治疗获得性血栓性血小板减少性紫癜, objectType=article, longId=157831, objectId=e6d915e83128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6d915e83128, replyNumber=0, likeNumber=71, createdTime=2019-01-13, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6d915e83128, moduleTitle=NEJM：Caplacizumab治疗获得性血栓性血小板减少性紫癜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6d915e83128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509521, encodeId=72eb15095215b, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病, objectType=article, longId=156443, objectId=a73015644339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a73015644339, replyNumber=0, likeNumber=72, createdTime=2018-12-24, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a73015644339, moduleTitle=APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a73015644339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509520, encodeId=3685150952091, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Blood：αβT/B细胞敲除后进行HLA相合性造血干细胞移植（αβhaplo-HSCT）可有效治疗急性白血病, objectType=article, longId=151767, objectId=d624151e67f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d624151e67f4, replyNumber=0, likeNumber=0, createdTime=2018-10-25, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d624151e67f4, moduleTitle=Blood：αβT/B细胞敲除后进行HLA相合性造血干细胞移植（αβhaplo-HSCT）可有效治疗急性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d624151e67f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509519, encodeId=7d931509519ce, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Cancer：APL第二次完全缓解后维持治疗三氧化二砷还有效吗？, objectType=article, longId=140233, objectId=46bd140233b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46bd140233b7, replyNumber=0, likeNumber=68, createdTime=2018-06-09, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46bd140233b7, moduleTitle=Cancer：APL第二次完全缓解后维持治疗三氧化二砷还有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46bd140233b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509518, encodeId=5ff8150951840, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Leukemia：老年APL患者：一线ATRA+蒽环类药物单药化疗方案怎么样？, objectType=article, longId=137656, objectId=14e413e656a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14e413e656a5, replyNumber=0, likeNumber=61, createdTime=2018-05-11, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14e413e656a5, moduleTitle=Leukemia：老年APL患者：一线ATRA+蒽环类药物单药化疗方案怎么样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14e413e656a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509517, encodeId=2825150951e03, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=单因素分析之Kaplan-Meier法（生存分析）, objectType=article, longId=134665, objectId=6378134665a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6378134665a8, replyNumber=0, likeNumber=69, createdTime=2018-04-11, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6378134665a8, moduleTitle=单因素分析之Kaplan-Meier法（生存分析）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6378134665a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达, objectType=article, longId=120620, objectId=7bfc1206208e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bfc1206208e, replyNumber=0, likeNumber=60, createdTime=2017-11-20, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bfc1206208e, moduleTitle=CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bfc1206208e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509515, encodeId=441f1509515d4, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=JCO:三氧化二砷可减低蒽环类药物在儿童APL中的用量，且不影响疗效？, objectType=article, longId=111007, objectId=c32f11100eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32f11100eea, replyNumber=0, likeNumber=57, createdTime=2017-08-28, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32f11100eea, moduleTitle=JCO:三氧化二砷可减低蒽环类药物在儿童APL中的用量，且不影响疗效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32f11100eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509514, encodeId=8e0c15095142f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Blood：APL细胞外染色质使凝血及纤溶恶化, objectType=article, longId=95432, objectId=d1709543225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1709543225, replyNumber=0, likeNumber=61, createdTime=2017-04-12, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1709543225, moduleTitle=Blood：APL细胞外染色质使凝血及纤溶恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1709543225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509513, encodeId=d3361509513bf, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报, objectType=article, longId=65458, objectId=5736654581e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5736654581e, replyNumber=0, likeNumber=70, createdTime=2016-03-26, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5736654581e, moduleTitle=苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5736654581e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509512, encodeId=f83715095127e, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=NEJM：Caplacizumab可缓解获得性血栓性血小板减少性紫癜，但增加出血危险, objectType=article, longId=63155, objectId=fb1d63155ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb1d63155ea, replyNumber=0, likeNumber=85, createdTime=2016-02-13, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb1d63155ea, moduleTitle=NEJM：Caplacizumab可缓解获得性血栓性血小板减少性紫癜，但增加出血危险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb1d63155ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509511, encodeId=c467150951191, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Kaplan-Meier生存分析中三种检验方法(log-rank、breslow、tarone)的比较, objectType=article, longId=62856, objectId=71f86285696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71f86285696, replyNumber=0, likeNumber=70, createdTime=2016-02-03, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71f86285696, moduleTitle=Kaplan-Meier生存分析中三种检验方法(log-rank、breslow、tarone)的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71f86285696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509510, encodeId=2bb4150951088, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=FDA批准Raplixa用于术中止血, objectType=article, longId=51375, objectId=e36b513e5ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e36b513e5ed, replyNumber=0, likeNumber=91, createdTime=2015-05-31, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e36b513e5ed, moduleTitle=FDA批准Raplixa用于术中止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e36b513e5ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509509, encodeId=d42a1509509c1, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=NEJM：基因组学研究质疑Lp-PLA2类药物darapladib, objectType=article, longId=45643, objectId=9fca45643ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fca45643ce, replyNumber=0, likeNumber=68, createdTime=2015-01-18, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fca45643ce, moduleTitle=NEJM：基因组学研究质疑Lp-PLA2类药物darapladib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fca45643ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509508, encodeId=ffbe1509508d8, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=APLCC 2014：来自亚太的肺癌资讯, objectType=article, longId=42784, objectId=d8d242e84e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d242e84e7, replyNumber=0, likeNumber=84, createdTime=2014-11-21, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d242e84e7, moduleTitle=APLCC 2014：来自亚太的肺癌资讯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d242e84e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509507, encodeId=7339150950ee3, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=APLCC 2014：阿法替尼可延长亚洲非小细胞肺癌患者总体生存期（LUX-Lung 6研究）, objectType=article, longId=42593, objectId=c717425931e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c717425931e, replyNumber=0, likeNumber=79, createdTime=2014-11-15, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c717425931e, moduleTitle=APLCC 2014：阿法替尼可延长亚洲非小细胞肺癌患者总体生存期（LUX-Lung 6研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c717425931e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509506, encodeId=a26715095065d, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=ESC 2014：Darapladib并不能降低急性冠脉综合征的主要心血管事件（SOLID-TIMI 52研究）, objectType=article, longId=39784, objectId=f40e39e8426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40e39e8426, replyNumber=0, likeNumber=62, createdTime=2014-09-02, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40e39e8426, moduleTitle=ESC 2014：Darapladib并不能降低急性冠脉综合征的主要心血管事件（SOLID-TIMI 52研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40e39e8426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509505, encodeId=b8c8150950507, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=JAMA：evolocumab降LDL-C（LAPLACE-2 试验）, objectType=article, longId=34791, objectId=e77c34e9112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77c34e9112, replyNumber=0, likeNumber=60, createdTime=2014-05-17, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77c34e9112, moduleTitle=JAMA：evolocumab降LDL-C（LAPLACE-2 试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77c34e9112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509504, encodeId=eb80150950478, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=NEJM：急性早幼粒细胞白血病（APL）砷剂耐药的基因突变机制, objectType=article, longId=34495, objectId=526d34495eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=526d34495eb, replyNumber=0, likeNumber=75, createdTime=2014-05-10, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=526d34495eb, moduleTitle=NEJM：急性早幼粒细胞白血病（APL）砷剂耐药的基因突变机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=526d34495eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509503, encodeId=b6cc15095037b, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）, objectType=article, longId=30220, objectId=a285302209d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a285302209d, replyNumber=0, likeNumber=58, createdTime=2014-02-06, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a285302209d, moduleTitle=Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a285302209d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APL

2020-05-29

风铃824 (审核中...)

前往app查看评论内容

#APL#

NEJM：Caplacizumab治疗获得性血栓性血小板减少性紫癜

2019-01-13

风铃824 (审核中...)

前往app查看评论内容

#APL#

APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病

2018-12-24

风铃824 (审核中...)

前往app查看评论内容

#APL#

Blood：αβT/B细胞敲除后进行HLA相合性造血干细胞移植（αβhaplo-HSCT）可有效治疗急性白血病

2018-10-25

风铃824 (审核中...)

前往app查看评论内容

#APL#

Cancer：APL第二次完全缓解后维持治疗三氧化二砷还有效吗？

2018-06-09

风铃824 (审核中...)

前往app查看评论内容

#APL#

Leukemia：老年APL患者：一线ATRA+蒽环类药物单药化疗方案怎么样？

2018-05-11

风铃824 (审核中...)

前往app查看评论内容

#APL#

单因素分析之Kaplan-Meier法（生存分析）

2018-04-11

风铃824 (审核中...)

前往app查看评论内容

#APL#

CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达

2017-11-20

风铃824 (审核中...)

前往app查看评论内容

#APL#

JCO:三氧化二砷可减低蒽环类药物在儿童APL中的用量，且不影响疗效？

2017-08-28

风铃824 (审核中...)

前往app查看评论内容

#APL#

Blood：APL细胞外染色质使凝血及纤溶恶化

2017-04-12

风铃824 (审核中...)

前往app查看评论内容

#APL#

苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报

2016-03-26

风铃824 (审核中...)

前往app查看评论内容

#APL#

NEJM：Caplacizumab可缓解获得性血栓性血小板减少性紫癜，但增加出血危险

2016-02-13

风铃824 (审核中...)

前往app查看评论内容

#APL#

Kaplan-Meier生存分析中三种检验方法(log-rank、breslow、tarone)的比较

2016-02-03

风铃824 (审核中...)

前往app查看评论内容

#APL#

FDA批准Raplixa用于术中止血

2015-05-31

风铃824 (审核中...)

前往app查看评论内容

#APL#

NEJM：基因组学研究质疑Lp-PLA2类药物darapladib

2015-01-18

风铃824 (审核中...)

前往app查看评论内容

#APL#

APLCC 2014：来自亚太的肺癌资讯

2014-11-21

风铃824 (审核中...)

前往app查看评论内容

#APL#

APLCC 2014：阿法替尼可延长亚洲非小细胞肺癌患者总体生存期（LUX-Lung 6研究）

2014-11-15

风铃824 (审核中...)

前往app查看评论内容

#APL#

ESC 2014：Darapladib并不能降低急性冠脉综合征的主要心血管事件（SOLID-TIMI 52研究）

2014-09-02

风铃824 (审核中...)

前往app查看评论内容

#APL#

JAMA：evolocumab降LDL-C（LAPLACE-2 试验）

2014-05-17

风铃824 (审核中...)

前往app查看评论内容

#APL#

NEJM：急性早幼粒细胞白血病（APL）砷剂耐药的基因突变机制

2014-05-10

风铃824 (审核中...)

前往app查看评论内容

#APL#

Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）

2014-02-06

科室
- - 订阅+
  - 更多科室
工具
服务